SCHEMBL16886156

SCHEMBL16886156

Cc1ccc(COc2cc(F)cc(Oc3ccc(-c4nn(C5CCCC5)c5ncnc(N)c45)cc3)c2)s1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 7/20 0.60
▸ LCK P06239 2/20 0.60
▸ LYN P07948 1/20 0.60
▸ PIK3CD O00329 13/20 0.54
▸ EGFR P00533 12/20 0.54
▸ SRC P12931 12/20 0.54
▸ KDR P35968 12/20 0.54
▸ PIK3CA P42336 12/20 0.54
▸ PIK3CB P42338 12/20 0.54
▸ PIK3CG P48736 12/20 0.54
▸ PRKDC P78527 12/20 0.54
▸ ABL1 P00519 11/20 0.54
▸ HCK P08631 11/20 0.54
▸ MTOR P42345 11/20 0.54
▸ EPHB4 P54760 11/20 0.54
▸ PI4KB Q9UBF8 9/20 0.54
▸ NUDT14 O95848 1/20 0.53
▸ NUDT5 Q9UKK9 1/20 0.53
▸ TEK Q02763 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886162 0.94 BTK (0.52) BTKLCKLYNPIK3CDEGFR
SCHEMBL16886204 0.92 BTK (0.49) BTKLCKLYNPIK3CDEGFR
SCHEMBL15613683 0.91 BTK (0.59) BTKLCKLYNPIK3CDEGFR
SCHEMBL16886173 0.87 BTK (0.50) BTKLCKLYNPIK3CDEGFR
SCHEMBL15613659 0.87 BTK (0.59) BTKLCKLYNPIK3CDEGFR
SCHEMBL15613529 0.87 BTK (0.61) BTKLCKLYNPIK3CDEGFR
SCHEMBL16886166 0.86 NUDT14 (0.57) BTKPIK3CDEGFRSRCKDR
SCHEMBL16886186 0.85 KDM4E (0.56) BTKLCKLYNPIK3CDEGFR
SCHEMBL15613748 0.85 BTK (0.59) BTKLCKLYNPIK3CDEGFR
SCHEMBL16886159 0.85 PIK3CD (0.49) BTKLCKPIK3CDEGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885LCK 3/4885LYN 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback